Valnivudine

Valnivudine (FV-100 free base), a proagent of CF-1743, is an orally active anti-herpes zoster (HZ) nucleoside analogue. CF-1743, a bicyclic nucleoside analog (BCNA), has highly specific antiviral activity against varicella-zoster virus (VZV) . Valnivudine is rapidly and extensively converted to CF-1743 in vivo[1][2].

Product Specifications

CAS Number

[956483-02-6]

Product Name Alternative

FV-100 (free base)

UNSPSC

12352005

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/valnivudine.html

Purity

98.02

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N=C2C(C=C(C3=CC=C(C=C3)CCCCC)O2)=CN1[C@]4([H])O[C@@H]([C@H](C4)O)COC([C@@H](N)C(C)C)=O

Molecular Formula

C27H35N3O6

Molecular Weight

497.58

References & Citations

[1]Nathan B Price, et al. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol. 2011 Dec;1 (6) :548-54.|[2]Helen S Pentikis, et al. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011 Jun;55 (6) :2847-54.|[3]C McGuigan, et al. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J Med Chem. 2000 Dec 28;43 (26) :4993-7.